UNIT 20.1 B16 as a Mouse Model for Human Melanoma

  1. Willem W. Overwijk,
  2. Nicholas P. Restifo

Published Online: 1 MAY 2001

DOI: 10.1002/0471142735.im2001s39

Current Protocols in Immunology

Current Protocols in Immunology

How to Cite

Overwijk, W. W. and Restifo, N. P. 2001. B16 as a Mouse Model for Human Melanoma. Current Protocols in Immunology. 39:20.1:20.1.1–20.1.29.

Author Information

  1. National Cancer Institute, NIH, Bethesda, Maryland

Publication History

  1. Published Online: 1 MAY 2001
  2. Published Print: OCT 2000

This is not the most recent version of the article. View current version (2 FEB 2015)


This unit details protocols for in vivo models of subcutaneous growth and pulmonary metastases of B16 melanoma. Therapeutic approaches include the use of B16.GM-CSF and rVVmTRP-1 to induce autoimmune vitiligo and tumor protection. The induction and use of gp100-specific therapeutic cytotoxic T lymphocytes (CTL) are discussed. Methods are also included for CTL induction, isolation and testing, CTL maintenance, and adoptive transfer. Support protocols detail the testing of mouse sera for presence of MDA-specific antibodies by immunoblotting and ELISA, respectively. Additional sections, including growing B16 melanoma, enumerating pulmonary metastases, and use of recombinant viruses for vaccination, are discussed together with safety concerns.